Alamar Biosciences Stock

alamarbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $248.57MM

Alamar Biosciences is a biotechnology company that is striving to develop a precision proteomics platform that is used in protein biomarker detection. Their flagship technology platform is called NULISA (Nanoparticle Uninhibited Luminescent Immunoassay), and it aims to help researchers detect protein biomarkers down to attomolar concentrations, or extremely small amounts. Alamar Biosciences seeks to use the NULISA platform to increase the speed of development for new diagnostic tests that can detect diseases early and improve treatment options. Alamar Biosciences founded in 2018 and headquartered in Fremont, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Alamar Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Alamar Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alamar Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Tod White JD
Chief Financial Officer & Chief Business Officer
Steve Chen Ph.D
Co-Founder & Chief Operating Officer
Xiao-Jun Ma Ph.D
Chief Technology Officer
Yiyuan Yin Ph.D
Co-Founder & Vice President of Technology
Yuling Luo Ph.D
Co-Founder & Chief Executive Officer

Board Members

Ian Ratcliffe
Sands Capital
Nisa Leung
Qiming Venture Partners

Alamar Biosciences’ stock FAQs


Can you buy Alamar Biosciences’ stock?

Alamar Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Alamar Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Alamar Biosciences’ stock?

Yes, you can sell stock of a private company like Alamar Biosciences. Forge can help you sell your Alamar Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Alamar Biosciences’ stock price?

Alamar Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Alamar Biosciences’ private market stock price with Forge Data.

What is Alamar Biosciences’ stock ticker symbol?

Alamar Biosciences does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Alamar Biosciences Raises $128M in Series C Financing

To expand its product line, Alamar Biosciences raises $128 million from investors.

Alamar Biosciences Raises $128 Million in Oversubscribed Series C Financing to Accelerate Commercialization of its Proteomics Platform

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the first close of $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days. This new capital brings Alamar's total funding to date to nearly $250 million. The financing round was led by Sands Capital and included participation from new financial and strategic investors as well as existing major investors.

Alamar Biosciences, Abcam Partner for Proteomics Research

The companies aim to bring together Alamar's immunoassay-based NULISA proteomics platform and Abcam's extensive antibody portfolio.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.